Jazz Pharmaceuticals, Inc.
by Michael VodickaSeptember 28, 2011 | Comments : 0 Recommended this article: (0)
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
Jazz Pharmaceuticals, Inc. develops and commercializes pharmaceutical products with an emphasis in epilepsy and narcolepsy. The company was founded in 2003 and has a market cap of $1.91 billion.
Very few stocks have held up in the tough market of the last few months. Put Jazz at the top of that list, recently spiking into a new all-time high on awesome Q2 results from late July and rising estimates.
Revenue for the period was up 58% from last year to $65 million. Earnings also came in strong at 75 cents, 9% ahead of the Zacks Consensus Estimate, where the company has an average earnings surprise of 7% over the last four quarters.
The good quarter was driven by the company's narcolepsy drug, Xyrem, where sales were up 67% from last year to $56 million.
Jazz has been able to use its earnings momentum to strengthen its financial profile, with cash and short-term investments jumping to $102 million from just $10 million last year.
We saw some pretty solid movement in estimates off the good quarter, with the current year adding 22 cents in the last month to $3.10. The next-year estimate is pegged at $4.03, a bullish 30% growth projection.
But in spite of the gains, the valuation picture still looks compelling, with a PEG ratio of .47 well below the benchmark of 1 for value.
On the chart, shares recently jumped into a new all-time high on the strong earnings momentum. Look for support from the long-term trend, take a look below.
Michael Vodicka is the Momentum Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Momentum Trader Service.
Please login to Zacks.com or register to post a comment.